Janus Henderson Group PLC grew its holdings in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 13.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,248,870 shares of the life sciences company’s stock after buying an additional 375,546 shares during the period. Janus Henderson Group PLC owned 3.80% of Integra Lifesciences worth $181,449,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in the company. Steward Partners Investment Advisory LLC acquired a new position in shares of Integra Lifesciences in the 2nd quarter valued at $26,000. Quadrant Capital Group LLC lifted its stake in shares of Integra Lifesciences by 223.0% in the first quarter. Quadrant Capital Group LLC now owns 646 shares of the life sciences company’s stock valued at $34,000 after buying an additional 446 shares in the last quarter. BNP Paribas Arbitrage SA lifted its stake in shares of Integra Lifesciences by 120.1% in the first quarter. BNP Paribas Arbitrage SA now owns 2,320 shares of the life sciences company’s stock valued at $129,000 after buying an additional 1,266 shares in the last quarter. World Asset Management Inc bought a new position in shares of Integra Lifesciences in the first quarter valued at $217,000. Finally, Stanley Laman Group Ltd. purchased a new stake in shares of Integra Lifesciences in the first quarter valued at about $223,000. Hedge funds and other institutional investors own 82.97% of the company’s stock.
Several analysts have recently commented on IART shares. BTIG Research set a $70.00 target price on shares of Integra Lifesciences and gave the company a “buy” rating in a report on Wednesday, July 24th. Wells Fargo & Co raised their price target on Integra Lifesciences from $55.00 to $68.00 and gave the stock a “market perform” rating in a research report on Thursday, July 25th. Zacks Investment Research downgraded Integra Lifesciences from a “buy” rating to a “hold” rating and set a $56.00 price target for the company. in a research report on Thursday, June 20th. JMP Securities raised their price target on Integra Lifesciences to $75.00 in a research report on Thursday, July 25th. Finally, BidaskClub upgraded Integra Lifesciences from a “hold” rating to a “buy” rating in a research report on Saturday, July 27th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company. Integra Lifesciences presently has a consensus rating of “Hold” and an average price target of $61.92.
Shares of Integra Lifesciences stock traded down $0.96 during trading on Wednesday, hitting $61.54. 4,633 shares of the stock were exchanged, compared to its average volume of 460,186. The firm has a market cap of $5.37 billion, a PE ratio of 25.40, a price-to-earnings-growth ratio of 1.97 and a beta of 1.09. The stock has a fifty day moving average of $58.01. Integra Lifesciences Holdings Corp has a 1-year low of $42.14 and a 1-year high of $66.41. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.76 and a quick ratio of 1.82.
Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.08. The company had revenue of $383.60 million for the quarter, compared to analyst estimates of $373.29 million. Integra Lifesciences had a net margin of 6.76% and a return on equity of 16.30%. Integra Lifesciences’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.60 EPS. Equities research analysts expect that Integra Lifesciences Holdings Corp will post 2.73 earnings per share for the current fiscal year.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Read More: Profit margin is different from the revenue
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.